Company intelligence / Profile preview
Oisín Biotechnologies
- Ownership
- Private
- Development stage
- Other
Overview
Preclinical data published showing significant increases in muscle mass (+50%) and strength (+100%) in animal models using follistatin gene therapy delivered by PLV. Demonstrated clearance of senescent cells leading to lifespan extension (>20% increase in median lifespan in aged mice). The PLV platform has passed Phase II human trials as a COVID vaccine delivery system, supporting safety[3][5][9].
- Therapeutic areas
- OtherNephrology
- Modalities
- Genetic medicines / gene therapyDNA and RNA therapeutics delivered via proprietary nonviral delivery systemSenolytic therapies targeting senescent cellsTherapies targeting muscle growth and adipocyte elimination
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Oisín Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oisín Biotechnologies.